Articles related to MELANOMA

With nearly ten years of follow-up, dabrafenib plus trametinib demonstrates a sustained improvement in survival outcomes for patients with stage III BRAF V600–mutated melanoma, presenting a viable long-term strategy in melanoma management.

A phase 3 trial comparing neoadjuvant ipilimumab plus nivolumab followed by surgery to adjuvant nivolumab alone in resectable stage III melanoma patients found a significantly higher event-free survival rate in the neoadjuvant group. This suggests that pre-surgical immunotherapy could lead to better patient outcomes.

Explore this development in metastatic melanoma treatment with the FDA’s accelerated approval of TIL therapy, a promising approach for patients who have exhausted other options.

Amtagvi’s approval introduces a novel approach in the treatment of advanced melanoma, employing patient-derived TIL-cell therapy to target tumors with precision, offering a beacon of hope for those with limited options.

Explore groundbreaking therapies in the pipeline: Onivyde for pancreatic cancer, showing marked survival benefits, and roluperidone, offering new hope in managing schizophrenia’s negative symptoms.

A look into the complexities of managing advanced melanoma with BRAF–MEK inhibitors, highlighting a case study where treatment-induced toxic effects posed significant diagnostic and therapeutic challenges.